Evaluation of Whole Body Diffusion- Weighted Imaging in the Staging and Treatment Response of Lymphoma Compared With Fluoride-Oxyglucose (FDG) PET/CT as a Reference Standard
DOI:
https://doi.org/10.17140/ROJ-2-114Keywords:
Diffusion magnetic resonance imaging, Lymphoma, Neoplasm staging, Positron-emission tomography, Whole body imagingAbstract
Introduction: Positron emission tomography/computed tomography (PET/CT) is currently considered
standard of practice for the management of lymphoma with sensitivity and specificity
approaching 100%. However, it is expensive, time-consuming and requires exposure to ionizing
radiation. Whole body-diffusion weighted imaging (WB-DWI), does not involve exposure
to ionizing radiation, is more widely available and can be performed within an acceptable time
frame. PET/CT will be used as a reference standard in the evaluation of the value of WB-DWI
in the initial staging and treatment response in patients with lymphoma.
Methods: Nine patients with newly diagnosed lymphoma and a pre-treatment PET/CT were
prospectively recruited. Patients were analyzed with both imaging modalities before treatment
initiation and at four-weeks post-completion of chemotherapy. The presence or absence of nodal
and extra-nodal involvement was independently assessed by two radiologists blinded to the
PET/CT findings. The PET/CT images were assessed by a single nuclear medicine physician.
Results: Compared to PET/CT, the overall sensitivity, specificity and accuracy of WB-DWI in
staging were 62%, 98% and 87% respectively and the overall specificity and accuracy for treatment
response were both 99%. Majority of false negative findings were a result of small nodes
which showed uptake on PET/CT but were either not identified or did not show restricted diffusion.
Further false negative and positive findings were due to reduced spatial resolution and
increased motion and susceptibility artefact on magnetic resonance imaging (MRI).
Conclusion: WB-DWI may be a viable alternative to PET/CT in the treatment response of
lymphoma. However, in terms of staging, PET/CT probably remains the imaging modality of
choice.
References
Cheson BD, Fisher RI, Barrington SF, et al. Recommenda-tions for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classi-fication. J Clin Oncol. 2014; 32(27): 3059-3068. doi: 10.1200/ jco.2013.54.8800
la Fougere C, Hundt W, Brockel N, et al. Value of PET/CT versus PET and CT performed as separate investigations in pa-tients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2006; 33(12): 1417-1425. doi: 10.1007/s00259-006-0171-x
Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for predic-tion of prognosis in patients with diffuse large B-cell lympho-ma: SUV-based assessment versus visual analysis. J Nucl Med. 2007; 48(10): 1626-1632. Web site. http://jnm.snmjournals.org/ content/48/10/1626.long. Accessed February 18, 2017.
Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progres-sion-free survival in Hodgkin lymphoma. Blood. 2006; 107(1): 52-59. doi: 10.1182/blood-2005-06-2252
Wu X, Kellokumpu-Lehtinen PL, Pertovaara H, et al. Diffu-sion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma-a pilot study: Comparison with 2-deoxy-2-fluoro- D-glucose-positron emis-sion tomography/computed tomography. NMR Biomed. 2011; 24(10): 1181-1190. doi: 10.1002/nbm.1689
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. Europe-an organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst. 2000; 92(3): 205-216. doi: 10.1093/ jnci/92.3.205
Miller AB, Hoogstraten B, Staquet M, Winkler A. Report-ing results of cancer treatment. Cancer. 1981; 47(1): 207- 214. doi: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Sumi M, Ichikawa Y, Nakamura T. Diagnostic ability of ap-parent diffusion coefficients for lymphomas and carcinomas in the pharynx. Eur Radiol. 2007; 17(10): 2631-2637. doi: 10.1007/ s00330-007-0588-z
Perrone A, Guerrisi P, Izzo L, et al. Diffusion-weighted MRI in cervical lymph nodes: Differentiation between benign and malignant lesions. Eur J Radiol. 2011; 77(2): 281-286. doi:
1016/j.ejrad.2009.07.039 10. Wieduwilt MJ, Valles F, Issa S, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: A pi-lot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012; 18(4): 1146-1155. doi: 10.1158/1078- 0432.CCR-11-0625
Wang HJ, Pui MH, Guo Y, Yang D, Pan BT, Zhou XH. Dif-fusion-weighted MRI in bladder carcinoma: The differentiation between tumor recurrence and benign changes after resection. Abdom Imaging. 2014; 39(1): 135-141. doi: 10.1007/s00261- 013-0038-0
Nural MS, Danaci M, Soyucok A, Okumus NO. Efficiency of apparent diffusion coefficients in differentiation of colorec-tal tumor recurrences and post-therapeutical soft-tissue chang-es. Eur J Radiol. 2013; 82(10): 1702-1709. doi: 10.1016/j. ejrad.2013.05.025
Kim S, Loevner L, Quon H, et al. Diffusion-weighted mag-netic resonance imaging for predicting and detecting early re-sponse to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res. 2009; 15(3): 986-994. doi: 10.1158/1078-0432.CCR-08-1287
Fujimoto H, Kazama T, Nagashima T, et al. Diffusion-weighted imaging reflects pathological therapeutic response and relapse in breast cancer. Breast Cancer. 2014; 21(6): 724-731. doi: 10.1007/s12282-013-0449-3
Kwee TC, Takahara T, Vermoolen MA, Bierings MB, Mali WP, Nievelstein RA. Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol. 2010; 40(10): 1592-602. doi: 10.1007/s00247-010-1775-7
Fischer MA, Nanz D, Hany T, et al. Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: A comparison with PET/CT. Eur Radiol. 2011; 21: 246-255. doi: 10.1007/s00330-010-1929-x
Metens T, Ferraresi KF, Farchione A, Moreno C, Bali MA, Matos C. Normal hepatic parenchyma visibility and ADC quan-tification on diffusion-weighted MRI at 3 T: Influence of age, gender, and iron content. Eur Radiol. 2014; 24(12): 3123-3133. doi: 10.1007/s00330-014-3353-0
Dohan A, Taylor S, Hoeffel C, et al. Diffusion-weighted MRI in Crohn’s disease: Current status and recommendations. J Magn Reson Imaging. 2016; 44(6): 1381-1396. doi: 10.1002/ jmri.25325
Cavalcanti Filho JL, de Souza Leao Lima R, de Souza Mach-ado Neto L, Kayat Bittencourt L, Domingues RC, da Fonseca LM. PET/CT and vascular disease: Current concepts. Eur J Ra-diol. 2011; 80: 60-67. doi: 10.1016/j.ejrad.2010.12.102
Mayerhoefer ME, Karanikas G, Kletter K, et al. Evalua-tion of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: Results of a prospective study in 140 patients. Clin Cancer Res. 2014; 20(11): 2984-2993. doi: 10.1158/1078-0432.CCR-13-3355
Albano D, Patti C, Lagalla R, Midiri M, Galia M. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the as-sessment of bone marrow involvement in patients with newly diagnosed lymphoma. J Magn Reson Imaging. 2017; 45(4): 1082-1089. doi: 10.1002/jmri.25439
van Ufford HM, Kwee TC, Beek FJ, et al. Newly diagnosed lymphoma: Initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/ CT. AJR Am J Roentgenol. 2011; 196: 662-669. doi: 10.2214/ AJR.10.4743
Stephane V, Samuel B, Vincent D, et al. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lym-phomas. Eur J Radiol. 2013; 82(11): 2011-2017. doi: 10.1016/j. ejrad.2013.05.042
Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: The added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol. 2011; 197(3): W384-W391. doi: 10.2214/ AJR.10.5692
Abdulqadhr G, Molin D, Astrom G, et al. Whole-body diffu-sion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol. 2011; 52(2): 173-180. doi: 10.1258/ar.2010.100246
Balbo-Mussetto A, Cirillo S, Bruna R, et al. Whole-body MRI with diffusion-weighted imaging: A valuable alterna-tive to contrast-enhanced CT for initial staging of aggressive lymphoma. Clin Radiol. 2016; 71(3): 271-279. doi: 10.1016/j. crad.2015.11.018
Chen Y, Zhong J, Wu H, Chen N. The clinical application of whole-body diffusion-weighted imaging in the early assess-ment of chemotherapeutic effects in lymphoma: The initial experience. Magn Reson Imaging. 2012; 30(2): 165-170. doi: 10.1016/j.mri.2011.09.019
Naganawa S, Kawai H, Fukatsu H, et al. Diffusion-weighted imaging of the liver: Technical challenges and prospects for the future. Magn Reson Med Sci. 2005; 4(4): 175-186.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Radiology (ROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
